ICICI Prudential Pharma Healthcare and Diagnostics (P H D) Fund · Direct · Growth
NAV
₹47.4100
as of 31 Jul 2026
Expense Ratio
—
see scheme documents
Lumpsum returns (CAGR)
- 1Y
- +7.17%
- 3Y
- +23.98%
- 5Y
- +16.79%
- Since Inception
- +21.33%
SIP returns (XIRR)
- 1Y
- +18.91%
- 3Y
- +18.71%
- 5Y
- +21.28%
- Since Inception
- +22.53%
Performance Comparison
Sectoral allocation
as of 30 Jun 2026- Pharmaceuticals & Biotechnology75.78%
- Healthcare Services11.50%
- Retailing5.35%
- Insurance1.33%
- Chemicals & Petrochemicals1.33%
- Healthcare Equipment & Supplies0.77%
Each sector links to the mutual funds most exposed to it.
Thinking about ICICI Prudential Pharma Healthcare and Diagnostics (P H D) Fund · Direct · Growth?
Talk to our AMFI-registered team — free, no pressure. We'll help you see if this fund fits your goals.
Fund Details
Available transactions
Portfolio holdings
portfolio shared with ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund - Cumulative Option
- 1Sun Pharmaceutical Industries Ltd.12.20%
- 2Dr. Reddy'S Laboratories Ltd.8.22%
- 3Mankind Pharma Ltd.6.98%
- 4Cipla Ltd.6.67%
- 5Alkem Laboratories Ltd.5.67%
- 6Divi'S Laboratories Ltd.5.57%
- 7Cohance Lifesciences Ltd.4.31%
- 8Medplus Health Services Ltd3.66%
- 9Max Healthcare Institute Ltd3.10%
- 10Syngene International Ltd.2.89%
Investment Objective
ICICI Prudential Pharma Healthcare and Diagnostics (P H D) Fund · Direct · Growth invests in stocks from a specific sector or theme, offering concentrated exposure to a particular area of the economy. These funds carry sector-specific risks but can deliver significant returns when the underlying sector performs well.
About This Fund
ICICI Prudential Pharma Healthcare and Diagnostics (P H D) Fund · Direct · Growth is a Sectoral / Thematic mutual fund offered by ICICI Prudential Mutual Fund. The fund has been operational for over 8 years.
Who Should Invest?
- •Investors with a high risk appetite seeking long-term wealth creation
- •Investors with an investment horizon of 5 years or more
- •SIP investors who can benefit from rupee cost averaging during market fluctuations